Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Proprietary Name Review Letter - Isoplate Solution

DEPARTMENT OF HEALTH & HUMAN SERVICES                                                     Public Health Service

                                                                                                                            Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448


Our STN: NDA BN090067                                                                           
B. Braun Medical, Inc.          
Attention: Susan Olinger
901 Marcon Boulevard
Allentown, PA  18109
Dear Ms. Olinger:
We have reviewed your submission to your new drug application (NDA) dated June 13, 2010, for Isoplate Solution in the 500mL EXCEL container, requesting a proprietary name review.
In consultation with CBER’s Advertising and Promotional Labeling Branch, we conclude that under the Federal Food, Drug, and Cosmetic Act and applicable regulations, your proposed proprietary name, Isoplate Solution, is acceptable at this time.
We will perform another proprietary name review of Isoplate Solution closer to the time of the action due date to ensure that we have not approved a conflicting proprietary name for another product in the interim.
If you have any questions, please call Iliana Valencia, Regulatory Project Manager, at (301) 827-6161.
 Basil Golding, M.D.
Division of Hematology        
Office of Blood Research and Review
Center for Biologics
  Evaluation and Research

Page Last Updated: 04/03/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English